United States · Investor

SymBiosis

Last cheque observed Jul 2026; 5 cheques on record.

Email

VC firmDeploying now

Series ASeries BBiotechnologyTherapeuticsLife Sciences

Deploying now
100%of best year2cheques in 12 months, 5 on record
Since the last cheque121days00hrs00min00sec
Median round$67MRounds led2 of 5Mostly inUnited States, 80%
Pitch SymBiosis

SymBiosis highlights

  1. 01

    2 cheques in the last 12 months

  2. 02

    Mostly Series C and Series A: 80% of its rounds

  3. 03

    Led 2 rounds

What they do

We partner with innovators building groundbreaking companies with the following characteristics Life-Threatening Disease With Hard Endpoint ... Novel Therapeutic Platform In Any Modality ... Lead Reaching Human Proof-Of-Concept ... Designed for manufacturabilityFrom their own website
Type
VC firm (from a list, unverified)
Cheque size
Not stated
Stages
Series ASeries B
Sectors
BiotechnologyTherapeuticsLife Sciences
Based in
Bentonville, United States
Cold pitches
Accepted

The record

Every round we can evidence, newest first5 appearances

  1. 2026

    2 rounds

  2. Jul
    FORE BiotherapeuticsSeries D · US · Ventureburn$67MLed
  3. Mar
    R1 TherapeuticsSeries A · US · TechStartups$78MWith 5 others
  4. 2025

    1 round

  5. Feb
    AdvanCellSeries C · AU · Startup Daily$112MLed
  6. 2019

    2 rounds

  7. Sept
    Vedanta BiosciencesSeries C · US · FinSMEs$17MWith 2 others
  8. May
    Vedanta BiosciencesSeries C · US · Businesswire$46MWith 8 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 6 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Who they invest alongside

The investors most often in the same rounds as SymBiosis. A count of rooms they were both in, not a relationship either has claimed.

AbingworthVC firm2rounds together

Recently backed

The latest companies SymBiosis put money into.

FORE Biotherapeutics$67M · Jul 2026AdvanCell$112M · Feb 2025Vedanta Biosciences$17M · Sept 2019

Quick answers about SymBiosis

What does SymBiosis invest in?

SymBiosis invests most often at Series C and Series A (80% of the rounds on record), in sectors such as Biotechnology, Therapeutics and Life Sciences.

How active is SymBiosis?

5 investments on record, 2 of them in the last 12 months, and it led 2. The most recent was in Jul 2026.

What has SymBiosis invested in recently?

Its most recent investments on record: FORE Biotherapeutics (Series D, Jul 2026), R1 Therapeutics (Series A, Mar 2026) and AdvanCell (Series C, Feb 2025).

How big are SymBiosis's cheques?

The median round it joins is $67M.

Does SymBiosis lead rounds?

Yes: it led 2 of its 5 investments on record (40%).

Where does SymBiosis invest?

Most of the companies it backs are in the United States (80%) and Australia (20%).

Is SymBiosis investing now?

Yes: it is actively investing, with 2 investments in the last 12 months.

Who does SymBiosis invest alongside?

Most often Abingworth (2 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it